BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 16452391)

  • 1. A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes.
    Cha HS; Boyle DL; Inoue T; Schoot R; Tak PP; Pine P; Firestein GS
    J Pharmacol Exp Ther; 2006 May; 317(2):571-8. PubMed ID: 16452391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation.
    Braselmann S; Taylor V; Zhao H; Wang S; Sylvain C; Baluom M; Qu K; Herlaar E; Lau A; Young C; Wong BR; Lovell S; Sun T; Park G; Argade A; Jurcevic S; Pine P; Singh R; Grossbard EB; Payan DG; Masuda ES
    J Pharmacol Exp Ther; 2006 Dec; 319(3):998-1008. PubMed ID: 16946104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Jun N-terminal kinase in rheumatoid arthritis.
    Han Z; Boyle DL; Aupperle KR; Bennett B; Manning AM; Firestein GS
    J Pharmacol Exp Ther; 1999 Oct; 291(1):124-30. PubMed ID: 10490895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of JNK by MKK-7 in fibroblast-like synoviocytes.
    Inoue T; Hammaker D; Boyle DL; Firestein GS
    Arthritis Rheum; 2006 Jul; 54(7):2127-35. PubMed ID: 16802349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor necrosis factor alpha-induced interleukin-32 is positively regulated via the Syk/protein kinase Cdelta/JNK pathway in rheumatoid synovial fibroblasts.
    Mun SH; Kim JW; Nah SS; Ko NY; Lee JH; Kim JD; Kim DK; Kim HS; Choi JD; Kim SH; Lee CK; Park SH; Kim BK; Kim HS; Kim YM; Choi WS
    Arthritis Rheum; 2009 Mar; 60(3):678-85. PubMed ID: 19248119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and activation of mitogen-activated protein kinase kinases-3 and -6 in rheumatoid arthritis.
    Chabaud-Riou M; Firestein GS
    Am J Pathol; 2004 Jan; 164(1):177-84. PubMed ID: 14695331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis.
    Han Z; Boyle DL; Chang L; Bennett B; Karin M; Yang L; Manning AM; Firestein GS
    J Clin Invest; 2001 Jul; 108(1):73-81. PubMed ID: 11435459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of c-Jun N-terminal kinase by MEKK-2 and mitogen-activated protein kinase kinase kinases in rheumatoid arthritis.
    Hammaker DR; Boyle DL; Chabaud-Riou M; Firestein GS
    J Immunol; 2004 Feb; 172(3):1612-8. PubMed ID: 14734742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-inflammatory actions of Syk inhibitors in macrophages involve non-specific inhibition of toll-like receptors-mediated JNK signaling pathway.
    Lin YC; Huang DY; Chu CL; Lin WW
    Mol Immunol; 2010 Apr; 47(7-8):1569-78. PubMed ID: 20138367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of the MAPK kinases MKK-4 and MKK-7 in rheumatoid arthritis and their role as key regulators of JNK.
    Sundarrajan M; Boyle DL; Chabaud-Riou M; Hammaker D; Firestein GS
    Arthritis Rheum; 2003 Sep; 48(9):2450-60. PubMed ID: 13130464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predominant activation of MAP kinases and pro-destructive/pro-inflammatory features by TNF alpha in early-passage synovial fibroblasts via TNF receptor-1: failure of p38 inhibition to suppress matrix metalloproteinase-1 in rheumatoid arthritis.
    Kunisch E; Gandesiri M; Fuhrmann R; Roth A; Winter R; Kinne RW
    Ann Rheum Dis; 2007 Aug; 66(8):1043-51. PubMed ID: 17223661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spleen tyrosine kinase mediates BEAS-2B cell migration and proliferation and human rhinovirus-induced expression of vascular endothelial growth factor and interleukin-8.
    Wang X; Mychajlowycz M; Lau C; Gutierrez C; Scott JA; Chow CW
    J Pharmacol Exp Ther; 2012 Feb; 340(2):277-85. PubMed ID: 22031919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The novel Syk inhibitor R406 reveals mechanistic differences in the initiation of GPVI and CLEC-2 signaling in platelets.
    Spalton JC; Mori J; Pollitt AY; Hughes CE; Eble JA; Watson SP
    J Thromb Haemost; 2009 Jul; 7(7):1192-9. PubMed ID: 19422460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor.
    Pine PR; Chang B; Schoettler N; Banquerigo ML; Wang S; Lau A; Zhao F; Grossbard EB; Payan DG; Brahn E
    Clin Immunol; 2007 Sep; 124(3):244-57. PubMed ID: 17537677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of spleen tyrosine kinase (Syk) at fertilization in Rhinella arenarum eggs.
    Mouguelar VS; Coux G
    Int J Dev Biol; 2014; 58(10-12):811-8. PubMed ID: 26154322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Syk-kinase inhibitor R406 impairs platelet activation and monocyte tissue factor expression triggered by heparin-PF4 complex directed antibodies.
    Lhermusier T; van Rottem J; Garcia C; Xuereb JM; Ragab A; Martin V; Gratacap MP; SiƩ P; Payrastre B
    J Thromb Haemost; 2011 Oct; 9(10):2067-76. PubMed ID: 21848694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of benzylidene derivatives as potent Syk inhibitors: synthesis, SAR analysis, and biological evaluation.
    Zhang L; Liu W; Mao F; Zhu J; Dong G; Jiang H; Sheng C; Miao L; Huang L; Li J
    Arch Pharm (Weinheim); 2015 Jul; 348(7):463-74. PubMed ID: 26032727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells.
    Gobessi S; Laurenti L; Longo PG; Carsetti L; Berno V; Sica S; Leone G; Efremov DG
    Leukemia; 2009 Apr; 23(4):686-97. PubMed ID: 19092849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-1 and TNF induction of matrix metalloproteinase-3 by c-Jun N-terminal kinase in trabecular meshwork.
    Hosseini M; Rose AY; Song K; Bohan C; Alexander JP; Kelley MJ; Acott TS
    Invest Ophthalmol Vis Sci; 2006 Apr; 47(4):1469-76. PubMed ID: 16565381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia.
    Buchner M; Baer C; Prinz G; Dierks C; Burger M; Zenz T; Stilgenbauer S; Jumaa H; Veelken H; Zirlik K
    Blood; 2010 Jun; 115(22):4497-506. PubMed ID: 20335218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.